Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean-Louis Excler

Showing results (61-70 of 112) with videos related to

Pageof 12
Sort By:
Plos One|March 11, 2014
Broad HIV epitope specificity and viral inhibition induced by multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adultsJakub Kopycinski, Peter Hayes, Ambreen Ashraf, et al.
Vaccine|September 10, 2020
The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of viral vector vaccinesRichard C Condit, Denny Kim, James S Robertson, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 26, 2023
Safety of Streptococcus pyogenes Vaccines: Anticipating and Overcoming Challenges for Clinical Trials and Post-Marketing MonitoringEdwin J Asturias, Jean-Louis Excler, James Ackland, et al.
Plos One|May 27, 2015
Accuracy of Clinical Diagnosis of Dengue Episodes in the RV144 HIV Vaccine Efficacy Trial in ThailandPunnee Pitisuttithum, Supachai Rerks-Ngarm, Donald Stablein, et al.
Vaccine|June 24, 2020
The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of nucleic acid (RNA and DNA) vaccinesDenny Kim, James S Robertson, Jean-Louis Excler, et al.
Plos One|February 14, 2019
Six-month follow up of a randomized clinical trial-phase I study in Indonesian adults and children: Safety and immunogenicity of Salmonella typhi polysaccharide-diphtheria toxoid (Vi-DT) conjugate vaccineBernie Endyarni Medise, Soedjatmiko Soedjatmiko, Iris Rengganis, et al.
Vaccine|March 25, 2025
Landscape analysis of invasive non-typhoidal salmonella (iNTS) disease and iNTS vaccine use case and demand: Report of a WHO expert consultationKate Emary, Adwoa D Bentsi-Enchill, Birgitte K Giersing, et al.
Vaccine|July 13, 2020
The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of protein vaccinesSonali Kochhar, Denny Kim, Jean-Louis Excler, et al.
Vaccine|June 28, 2016
Unique safety issues associated with virus-vectored vaccines: Potential for and theoretical consequences of recombination with wild type virus strainsRichard C Condit, Anna-Lise Williamson, Rebecca Sheets, et al.
Vaccine|October 19, 2020
Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) standardized template for collection of key information for benefit-risk assessment of live-attenuated viral vaccinesMarc Gurwith, Richard C Condit, Jean-Louis Excler, et al.
Pageof 12

Showing results (61-70 of 112) with videos related to

Sort By:
Pageof 12
Plos One|March 11, 2014
Broad HIV epitope specificity and viral inhibition induced by multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adultsJakub Kopycinski, Peter Hayes, Ambreen Ashraf, et al.
Vaccine|September 10, 2020
The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of viral vector vaccinesRichard C Condit, Denny Kim, James S Robertson, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 26, 2023
Safety of Streptococcus pyogenes Vaccines: Anticipating and Overcoming Challenges for Clinical Trials and Post-Marketing MonitoringEdwin J Asturias, Jean-Louis Excler, James Ackland, et al.
Plos One|May 27, 2015
Accuracy of Clinical Diagnosis of Dengue Episodes in the RV144 HIV Vaccine Efficacy Trial in ThailandPunnee Pitisuttithum, Supachai Rerks-Ngarm, Donald Stablein, et al.
Vaccine|June 24, 2020
The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of nucleic acid (RNA and DNA) vaccinesDenny Kim, James S Robertson, Jean-Louis Excler, et al.
Plos One|February 14, 2019
Six-month follow up of a randomized clinical trial-phase I study in Indonesian adults and children: Safety and immunogenicity of Salmonella typhi polysaccharide-diphtheria toxoid (Vi-DT) conjugate vaccineBernie Endyarni Medise, Soedjatmiko Soedjatmiko, Iris Rengganis, et al.
Vaccine|March 25, 2025
Landscape analysis of invasive non-typhoidal salmonella (iNTS) disease and iNTS vaccine use case and demand: Report of a WHO expert consultationKate Emary, Adwoa D Bentsi-Enchill, Birgitte K Giersing, et al.
Vaccine|July 13, 2020
The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of protein vaccinesSonali Kochhar, Denny Kim, Jean-Louis Excler, et al.
Vaccine|June 28, 2016
Unique safety issues associated with virus-vectored vaccines: Potential for and theoretical consequences of recombination with wild type virus strainsRichard C Condit, Anna-Lise Williamson, Rebecca Sheets, et al.
Vaccine|October 19, 2020
Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) standardized template for collection of key information for benefit-risk assessment of live-attenuated viral vaccinesMarc Gurwith, Richard C Condit, Jean-Louis Excler, et al.
Pageof 12